https://clinicaltrials.gov/ct2/show/NCT03927144?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Episodic Migraine
Interventions : Drug: Erenumab; Drug: Oral Prophylactic
Sponsors : Amgen; Novartis
Not yet recruiting
Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients
NCT03927144
Thu, 25 Apr 2019 12:00:00 EDT
Last Update Posted: 04/25/19 07:33AM